Navigation Links
Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
Date:11/5/2008

11-dehydro thromboxane B2 (11dhTxB2) levels affirmed as independent predictor of heart attack and stroke risk in aspirin-treated patients

DENVER, Nov. 5 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test November 9 - 11 in booth No. 2536 at the American Heart Association Scientific Sessions 2008 in New Orleans, La.

New CHARISMA trial findings recently published in the American Heart Association's peer-reviewed medical journal Circulation confirm that elevated urinary levels of the biomarker 11-dehydro thromboxane B2 (11dhTxB2) indicate an increased risk of heart attack, stroke and cardiac death.

The AspirinWorks Test by Corgenix is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.

"The American Heart Association conference is an ideal forum in which to discuss the findings on the relationship between elevated 11dhTxB2 levels and cardiovascular risk from the powerful and respected CHARISMA trial," said Gordon Ens, clinical director of Corgenix Medical Corporation. "This well-designed, prospective outcome study demonstrates the potential value of the AspirinWorks Test for optimizing an individual's aspirin therapy."

CHARISMA is a multinational, multicenter, randomized, parallel group, double-blind trial involving 15,603 patients with either clinically established cardiovascular disease or multiple risk factors. The CHARISMA sub-study involved a total of 3,261 aspirin-treated patients from 224 sites in 12 countries.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories as well as direct to consumers th
'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
10. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
11. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... 2014 Research and Markets ( ... "Glucose Sensors: the Next Generation" report ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of small-scale ... hope for a better future to millions of ... measure glucose levels accurately and reliably have the ...
(Date:12/12/2014)... Pittcon is pleased to announce the ... 2,000 technical presentations offered in symposia, oral sessions, ... covers a wide range of applications such as, ... environmental, food science, fuels/energy, genomics, lab management, materials ... Technical Program begins on Sunday, March 8 and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... Cormack, president and chief executive officer of OncoGenex, has ... The Year(R). The Ernst & Young Entrepreneur Of The ... entrepreneurs that are building successful, dynamic businesses. , "I ...
... ... Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes, a method ... for the production and control of qualitative supersaturation trajectories. , ... (PRWEB) October 9, 2009 -- The quantitative ...
... , ... is announcing its 2010 Best Practices awards program and is opening the call for ... of technology and strategic innovation--initiatives and collaborations that manifestly improve some facet of the ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 2OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 3Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 2The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation 2The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation 3
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Two scientists from Cold Spring Harbor Laboratory (CSHL) are ... genetic mutation that causes Joubert Syndrome. JBTS, as it ... that is very rare in the general population but ... The study was published in collaboration with Dor Yeshorim, ...
... crops relies on a relatively stable climate, not dramatic ... evolutionary, ecological, genetic and agronomic considerations, Dr. Shahal Abbo, ... Hebrew University of Jerusalem, Israel, and colleagues, demonstrate why ... domestication in the Near East. Rather, the variety of ...
... COLUMBIA, Md. , Jan. 12 Cylex Incorporated® ... Panel approved the creation of new CPT coding based on ... the fact that existing CPT codes insufficiently captured all steps ... , In an effort to keep customers informed of these ...
Cached Biology News:CSHL scientists use next-gen sequencing to rapidly discover genetic cause of devastating disorder 2Stable climate and plant domestication linked 2Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay 2Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay 3
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: